PBPK Modeling & Simulation

LEO Pharma Joins Certara’s PBPK Simcyp Simulator Consortium

PRINCETON, NJ – Dec. 10, 2019 – LEO Pharma has licensed Certara’s proprietary Simcyp®️ Population-based Simulator and joined its Consortium.

Topics:

What’s New in the Simcyp Simulator v19?

This webinar will explain how the latest updates to the Simcyp Simulator v19, a PBPK M&S platform, will accelerate developing safer, more effective medications.

Topics:

Predicting Human Oral Bioavailability: Comparison of In Vivo Animal (Rat- Dog- and Monkey) Studies versus Mechanistic In Vitro In Vivo Extrapolation (IVIVE) Based Predictions

Topics:

Fitting PBPK Model Parameters within Simcyp Engine Using Simcyp-R Package

Topics:

Development of a PBPK model for the prediction of Amiodarone pharmacokinetics in fed and fasted state using the Advanced Dissolution, Absorption and Metabolism (ADAM) model

Topics:

Development of a Permeability-Limited Cardiac Physiologically-Based Pharmacokinetic Model for Predicting Cardiac Exposure

Topics:

Dosing corrected for species differences in toxicokinetics using PBPK modelling predicts equivalent reactive metabolite burden following acetaminophen overdose

Topics:

Predicting Human Oral Bioavailability: Comparison of in vivo animal (rat, dog, and monkey) studies versus mechanistic in vitro in vivo extrapolation (IVIVE) based predictions

Topics:

Predictive Performance of Caffeine Preterm PBPK Model and Effect of Time-Varying Physiology on Predictions

Topics:

Prediction of Drug-Drug Interaction between Phenobarbital and Theophylline in Children using Physiologically-Based Pharmacokinetic Modelling

Topics:

Development of a PBPK model for the prediction of Amiodarone pharmacokinetics in fed and fasted state using ADAM model

Topics:

The Certara Quantitative Systems Toxicology & Safety (QSTS) Pharma Consortium: Overview and Invitation to Join

Topics:

Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid

Topics:

Prediction of mAb disposition in hepatic impairment – Evolocumab as a case study

Topics:

Use of a physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model to guide dose adjustments to S-warfarin in different populations

Topics:

Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed PBPK Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions

Topics:

Accounting for CYP2C19 mechanism based inhibition and CYP1A2 induction in a PBPK model for omeprazole

Topics:

Physiological verification of a geriatric population using the Simcyp R package

Topics:

Estimation of Effective pKa of Bicarbonate Buffer

Topics:

Quantification of Human Blood-Brain Barrier Transporters in Health and in Dementia by Global and Targeted Proteomics

Topics:

Contact Us

Contact Us

Download Phoenix 8.2

Contact Us

Learn More with Certara

Contact Us

Solution: PBPK Modeling & Simulation

LEO Pharma Joins Certara’s PBPK Simcyp Simulator Consortium

What’s New in the Simcyp Simulator v19?

Predicting Human Oral Bioavailability: Comparison of In Vivo Animal (Rat- Dog- and Monkey) Studies versus Mechanistic In Vitro In Vivo Extrapolation (IVIVE) Based Predictions

Fitting PBPK Model Parameters within Simcyp Engine Using Simcyp-R Package

Development of a PBPK model for the prediction of Amiodarone pharmacokinetics in fed and fasted state using the Advanced Dissolution, Absorption and Metabolism (ADAM) model

Development of a Permeability-Limited Cardiac Physiologically-Based Pharmacokinetic Model for Predicting Cardiac Exposure

Dosing corrected for species differences in toxicokinetics using PBPK modelling predicts equivalent reactive metabolite burden following acetaminophen overdose

Predicting Human Oral Bioavailability: Comparison of in vivo animal (rat, dog, and monkey) studies versus mechanistic in vitro in vivo extrapolation (IVIVE) based predictions

Predictive Performance of Caffeine Preterm PBPK Model and Effect of Time-Varying Physiology on Predictions

Prediction of Drug-Drug Interaction between Phenobarbital and Theophylline in Children using Physiologically-Based Pharmacokinetic Modelling

Development of a PBPK model for the prediction of Amiodarone pharmacokinetics in fed and fasted state using ADAM model

The Certara Quantitative Systems Toxicology & Safety (QSTS) Pharma Consortium: Overview and Invitation to Join

Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid

Prediction of mAb disposition in hepatic impairment – Evolocumab as a case study

Use of a physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model to guide dose adjustments to S-warfarin in different populations

Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed PBPK Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions

Accounting for CYP2C19 mechanism based inhibition and CYP1A2 induction in a PBPK model for omeprazole

Physiological verification of a geriatric population using the Simcyp R package

Estimation of Effective pKa of Bicarbonate Buffer

Quantification of Human Blood-Brain Barrier Transporters in Health and in Dementia by Global and Targeted Proteomics